A Phase III, Parallel Group, Randomized, Open-label, Multi-centre Clinical Trial of Zoledronic Acid in Males Receiving Androgen Deprivation Therapy for Advanced Prostate Cancer

Trial Profile

A Phase III, Parallel Group, Randomized, Open-label, Multi-centre Clinical Trial of Zoledronic Acid in Males Receiving Androgen Deprivation Therapy for Advanced Prostate Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2014

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Zometa ASAP
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Jan 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top